|
Press
Releases |
14
April 2008 |
Quintessence
Biosciences, Inc. Presents IND-ENabling Toxicology Data at Cancer
Meeting (PDF)
At the Annual Meeting of the American Association for Cancer
Research today, Quintessence Biosciences presented the results
of the IND-enabling toxicology
studies for the Company’s lead cancer drug candidate, QBI-139. |
| |
5 Febraury 2008 |
| Althea
Technologies Chosen by Quintessence Biosciences to Produce Lead
Protein Oncology Drug (PDF)
Althea Technologies, Inc., a leading provider of innovative technologies
and services for pharmaceutical development and manufacturing,
announced today that is has been awarded a contract from Quintessence
Biosciences under a manufacturing supply agreement to produce
the firm’s first drug candidate. |
| |
30 November 2007 |
| Quintessence
Biosciences, Inc. Announces Award of Two Federal Grants to Support
Development of EVade™ Ribonuclease Products
(PDF) The
National Cancer Institute awarded Quintessence Biosciences two
Phase 1 Small Business Innovation Research grants. |
| |
22 October 2007 |
| Quintessence
Biosciences, Inc. Presents Additional Data on Lead Candidate (PDF)
Quintessence Biosciences presented information about
the company’s lead candidate QBI-139 at the International
Conference on Molecular Targets and Cancer Therapeutics - the
premier international meeting featuring novel cancer therapeutics. |
| |
16
April 2007 |
| Quintessence
Biosciences, Inc. Presents Pre-clinical Toxicology Data at Cancer
Meeting (PDF)
At the Annual Meeting of the American Association for Cancer Research
today, Quintessence Biosciences presented pre-clinical toxicology
data on the performance of the Company’s lead cancer drug
candidate, QBI-139 for treatment of patients with solid tumors. |
| |
8
February 2007 |
| Quintessence
Biosciences, Inc. Names Laura Strong, Ph.D. as President
(PDF)
Quintessence Biosciences today announced the appointment of Laura
Strong, Ph.D. to the position of the Company’s President
and Chief Operating Officer. |
| |
9
November 2006 |
| Quintessence
Biosciences Confirms Selection of EVade™ Ribonuclease Cancer
Treatment for Late Stage Pre-Clinical Studies (PDF)
Quintessence Biosciences, Inc. today confirmed the selection of
a compound from its proprietary EVade™ Ribonuclease program
for advancement to pre-clinical testing and human clinical trials. |
| |
19
April 2005 |
| Quintessence
Biosciences Announces Start of Non-Clinical Studies on Lead Candidate
QBI-139 at the 2005 Annual Meeting of the American Association
of Cancer Research (PDF) |
| |
17
September 2004 |
| Quintessence
Biosciences to present at BioContact Quebec 2004 (PDF)
Quintessence Biosciences, Inc. announced today that it will present
at BioContact Quebec 2004, a biopharmaceutical partnership symposium
at 4:00 p.m. eastern time on October 7, 2004. |
| |
18
June 2004 |
|
Quintessence Biosciences, Inc. names Scientific Advisory
Board (PDF)
Howard H. Bailey, Thomas J. Burke, Anthony J. Clemento Jr., and
Paul M. Sondel have agreed to join the Founders, Laura L. Kiessling
and Ronald T. Raines on the Scientific Advisory Board. |
| |
25
July 2003 |
| Three
Prominent Business Leaders to Assist Quintessence Biosciences,
Inc. (PDF)
Christopher Hornung (President and CEO of Pacific Cycle, Madison),
Theodore R. ("Ted") Rolfs (Managing Director of Red
Top Capital, Milwaukee), and David G. Walsh (partner of the Madison
office of Foley & Lardner) have agreed to join the Quintessence
Biosciences, Inc. Business Advisory Board. |
| |
22
May 2003 |
| Quintessence
Biosciences, Inc. secures $3 million in financing (PDF)
Quintessence Biosciences, Inc. of Madison announced today that
it has closed on transactions that will bring over $3 million
of new financing to the biotechnology company. |
| |
